Loading stock data…
DexCom, Inc. (DXCM)
$71.54+1.06 (+1.50%)
Market ClosedLast close Jul 24
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DexCom, Inc. in the Healthcare sector is trading at $71.54 with a market capitalization of $28.1B. Wall Street consensus targets $85.75 (24 analysts), implying a +19.9% move over the next 12 months. The stock is currently 20% below its 52-week high of $89.98, remaining 6.0% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +19.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.19B↓ | $1.26B↑ | $1.21B↑ | $1.16B↑ | $1.04B |
| Gross Profit | $750.30M↓ | $792.70M↑ | $731.40M↑ | $688.80M↑ | $589.00M |
| Operating Income | $255.30M↓ | $323.00M↑ | $242.50M↑ | $212.60M↑ | $133.70M |
| Net Income | $199.50M↓ | $267.30M↓ | $283.80M↑ | $179.80M↑ | $105.40M |
Peer Comparison
JNJUNHPFE
Fundamentals
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$28.08B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
31.23
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.40
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
31.47%
Volume
Today's trading volume
2.76M
Recent News
DexCom (DXCM) Earnings Expected to Grow: Should You Buy?
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Medical Stocks Lagging DexCom (DXCM) This Year?
Here is how DexCom (DXCM) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
2 Cash-Heavy Stocks on Our Buy List and 1 We Avoid
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
What Investors Don’t Understand About Abbott Laboratories
Wall Street still prices Abbott like a slow-and-steady dividend stalwart, but a pair of massive strategic moves beneath the surface suggests that framing may be costing investors a significant opportunity.
DXCM Secures Health Canada Authorization for Dexcom G7 15 Day CGM
DexCom's G7 15 Day wins Health Canada authorization, offering longer wear, high accuracy and smart features for adults with diabetes.